Life Sciences

Life Sciences

Key Capital Life Sciences is focused on opportunities to bring breakthrough products to market. Key Capital has agreement to license the use of a promising and unique range of immunotherapies commencing in Central America. The lead immunotherapy product has demonstrated breakthrough success in the treatment of liver cancer.

Key Capital Life Sciences has licensed the Immunitor range of immunotherapy products with an initial focus on Guatemala and Costa Rica. Subject to performance and conditions we have the opportunity of expanding our licensed territory in Latin America. Our initial focus is on the Immunitor immunotherapy oral vaccines for late stage and terminal cancers.

Key Capital is in discussion with established cancer treatment centers and practicing oncology professionals in Guatemala and Costa Rica to establish treatment centers.

Phase II Clinical Trial

In a recent open-label Phase II study of Hepko-V5 oral immunotherapeutic vaccine conducted in 75 patients with late stage hepatocellular carcinoma (HCC), 90% of patients were alive after a median 12 months of follow up, as reported in open access Journal of Hepatocellular Carcinoma. A YouTube testimonial of a liver cancer patient's successful Hepko-V5 treatment is available.

The study showed that the once-daily tablet of Immunitor Inc’s oral immunotherapeutic vaccine, hepcortespenlisimut-L (Hepko-V5), was safe and effective in treating patients with advanced liver cancer - inoperable hepatocellular carcinoma (HCC). This study also showed that after a median 2 months of treatment 50 out of 75 patients had their hepatic tumor marker, alpha-fetoprotein or AFP, decline, which indicates that two thirds of the study population responded to immunotherapy, since the decrease in AFP was correlated with tumor shrinkage. Those who had AFP down to normal levels experienced tumor clearance, meaning they had survived. There were 12 patients (16%) in the study who ended up with normalized AFP below 10 IU/ml. No adverse events or toxicity were observed at any time. Considering that no validated immunotherapy for liver cancer has emerged after 20 years of research efforts, these are promising results. An ongoing Phase III study at the Mongolian National Cancer Center is aimed to confirm the potential of hepcortespenlisimut-L in placebo-controlled, randomized setting.